CSE: 2017-1117 - Fundamental Change - Gravis Energy Corp./Biocure Technology Inc.
/EINPresswire.com/ -- TORONTO, ONTARIO--(Marketwired - Nov 28, 2017) - Biocure Technology Inc., the issuer resulting from a Fundamental Change of Gravis Energy Corp. has been approved for listing.
Listing and disclosure documents will be available at thecse.com on the trading date.
Biocure is a biopharmaceutical company, specializing in the development and commercialization of major biosimilar products. Biocure is currently conducting clinical trials of its biosimilar candidates of Interferon Beta 1b, Filgrastim and Ranibizumab.
Biocure Technology Inc., l'émetteur résultant d'un changement fondamental de Gravis Energy Corp. a été approuvé pour inscription.
Les documents de divulgation et d'inscription seront disponibles à thecse.com à la date de négociation.
Biocure est une société biopharmaceutique spécialisée dans le développement et la commercialisation de produits biosimilaires majeurs. Biocure mène actuellement des essais cliniques de ses candidats biosimilaires d'interféron bêta 1b, de filgrastim et de ranibizumab.
| Issuer/Émetteur: | Biocure Technology Inc. |
| Security Type/Titre: | Common Shares/Actions ordinaires |
| Symbol(s)/Symbole(s): | CURE |
| Number of securities issued and outstanding/ Titres émis et en circulation: | 93 387 632 |
| Number of Securities reserved for issuance/ Titres réservés pour émission: | 3 790 680 |
| CSE Sector/Catégorie: | Life Sciences/Sciences biologiques |
| CUSIP: | 09075T 10 7 |
| ISIN: | CA 09075T 10 7 5 |
| Boardlot/Quotité: | 500 |
| Trading Currency/Monnaie de négociation: | CDN$/$CDN |
| Trading Date/Date de negociation: | le 29 novembre/November 2017 |
| Other Exchanges/Autres marches: | N/A |
| Fiscal Year end /Clôture de l'exercice financier: | December 31/Le 31 décembre |
| Transfer Agent/Agent des transferts: | Computershare Trust Company of Canada |
Canadian Securities Exchange (CSE)
Listings
(416) 367-7340
Listings@thecse.com
www.thecse.com
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
